Skip to main content
. 2023 Aug 30;13:14237. doi: 10.1038/s41598-023-41030-7

Figure 5.

Figure 5

The hazard of disease recurrence and progression after 3 years of follow-up for 77, 60 and 41 CRC patients at baseline, after 3 months of 5-FU therapy, after 6 months of 5-FU therapy, respectively. Data presented as median logHR (95% CI) of disease recurrence and progression after 3 years of follow-up. Abbreviations: HR: hazard ratio, CI: confidence interval.